Clinicopathological Aspect of Dysglycemia in Naive and Diabetic Rats induced by the Fluoroquinolone Antibacterial Gatifloxacin

To ascertain the clinicopathological process underlying dysglycemia induced by the fluoroquinolone antibacterial gatifloxacin (GFLX), we orally administered 100 or 300 mg/kg/day to male clinically healthy (naive) or spontaneous type II (diabetic) Goto-Kakizaki rats for 15 days (days 1 to 15). Treatment of naive rats with GFLX led to decreased blood glucose concentrations at 100 mg/kg/day on day 1. In diabetic animals, markedly increased blood...